

Corrigendum: SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines

Pather, Shanti; Madhi, Shabir A.; Cowling, Benjamin J.; Moss, Paul; Kamil, Jeremy P.; Ciesek, Sandra; Muik, Alexander; Türeci, Özlem

DOI:

[10.3389/fimmu.2023.1232965](https://doi.org/10.3389/fimmu.2023.1232965)

License:

Creative Commons: Attribution (CC BY)

Document Version

Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Pather, S, Madhi, SA, Cowling, BJ, Moss, P, Kamil, JP, Ciesek, S, Muik, A & Türeci, Ö 2023, 'Corrigendum: SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines', *Frontiers in immunology*, vol. 14, 1232965. <https://doi.org/10.3389/fimmu.2023.1232965>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.



OPEN ACCESS

APPROVED BY

Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Shanti Pather
Shanti.Pather@biontech.de

RECEIVED 01 June 2023

ACCEPTED 02 June 2023

PUBLISHED 12 June 2023

CITATION

Pather S, Madhi SA, Cowling BJ, Moss P, Kamil JP, Ciesek S, Muik A and Türeci Ö (2023) Corrigendum: SARS-CoV-2

Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines.

Front. Immunol. 14:1232965.

doi: 10.3389/fimmu.2023.1232965

COPYRIGHT

© 2023 Pather, Madhi, Cowling, Moss, Kamil, Ciesek, Muik and Türeci. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines

Shanti Pather^{1*}, Shabir A. Madhi², Benjamin J. Cowling³, Paul Moss⁴, Jeremy P. Kamil⁵, Sandra Ciesek⁶, Alexander Muik¹ and Özlem Türeci¹

¹BioNTech, Mainz, Germany, ²South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ³School of Public Health, The University of Hong Kong, Hong Kong, Hong Kong SAR, China, ⁴Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom, ⁵Department of Microbiology and Immunology, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, United States, ⁶Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany

KEYWORDS

sub-lineage, BA.1, vaccine, disease burden, Omicron

A Corrigendum on

SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines

by Pather S, Madhi SA, Cowling BJ, Moss P, Kamil JP, Ciesek S, Muik A and Türeci Ö (2023). *Front. Immunol.* 14:1130539. doi: 10.3389/fimmu.2023.1130539

In the published article, there was an error in the legend for [Figure 2](#) as published. The figure legend was displayed as “Favored cell entry pathways of (A) Delta variant and (B) BA.1. Delta favors cell surface fusion, whereas BA.1 favors endosomal entry. Evidence suggests that BA.4 and BA.5 sub-lineages may be partially reverting back towards cell surface fusion, due to increased fusogenicity compared with BA.1. Adapted from Tang et al. *Antiviral Res* (2020); 178:104792 (32)”. Furthermore, The figure legend included incorrect spelling of Cathepsin L as Cathespin L. The corrected legend appears below.

“Favored cell entry pathways of (A) BA.1 and (B) Delta variant. Delta favors cell surface fusion, whereas BA.1 favors endosomal entry. Evidence suggests that BA.4 and BA.5 sublineages may be partially reverting back towards cell surface fusion, due to increased fusogenicity compared with BA.1. Adapted from Tang et al. *Antiviral Res* (2020); 178:104792 (32).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.




FIGURE 2

Favored cell entry pathways of (A) BA.1 and (B) Delta variant. Delta favors cell surface fusion, whereas BA.1 favors endosomal entry. Evidence suggests that BA.4 and BA.5 sub-lineages may be partially reverting back towards cell surface fusion, due to increased fusogenicity compared with BA.1. Adapted from Tang et al. Antiviral Res (2020);178:104792 (32).

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.